IL13RA2 and neoplasm: The potency of CAR‐T cells was first assessed by cell killing assay against IL‐13Rα2 positive U251 and U87MG malignant glioma tumour cells lines, as these tumour cell lines express high levels of IL‐13Rα2 (Figure 4A).